跳至主要内容
临床试验/JPRN-jRCT2080221805
JPRN-jRCT2080221805未知2 期

Phase II/III Clinical Trial of TO-203 -Efficacy and Safety Trial in Patients with HDM-induced Asthma

TORII PHARMACEUTICAL CO., LTD.0 个研究点目标入组 900 人开始时间: 2012年5月29日最近更新:

试验速览

阶段
2 期
入组人数
900

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 <= 64age old(—)
性别
All

入选标准

  • (1) HDM-specific IgE antibodies >= Class 3
  • (2) Positive HDM-allergen scratch or prick test
  • (3) Asthmatic symptoms were treated with ICS
  • (4) Dicumented reversible airway obstruction
  • (5) FEV1 > 70% of the predicted value

排除标准

  • (1) Patients who have perennial symptoms of asthma or rhinitis due to regular exposure to antigens (excluding HDM).
  • (2) Patients who received immunotherapy with HDM allergen-containing products (e.g., house dust) for at least 1 month during 5 years before the first day of observation.
  • (3) Patients who are on immunotherapy other than HDM allergen-containing products on the first day of observation.
  • (4) Patients with a history of serious adverse drug reactions due to immunotherapy.
  • (5) Patients who were hospitalized due to worsening of asthma within 3 months before the first day of observation.

研究者

相似试验